MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$11,756,548
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from sale of common sto...
Proceeds from sale of common sto...
Proceeds from the sale of invest...
Others
Negative Cash Flow Breakdown
Purchase of investments
Net loss
Accounts payable and accrued exp...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-11,557,002
-10,086,687
-10,687,830
-18,750,783
Stock-based compensation
978,140
575,565
570,796
470,471
Depreciation
90,993
91,577
52,114
96,986
Amortization of right of use asset
39,891
39,189
38,517
37,869
Loss on disposal of fixed assets
0
-34,153
-
-
Realized gain on available-for-sale securities
38,683
10,648
-
-
Tax receivable
-
725
-12,379
-21,564
Prepaid expenses and other current assets
-12,044
866,595
191,348
-50,572
Accounts payable and accrued expenses
-1,225,630
432,207
-790,864
1,035,121
Operating lease liability
-35,983
-35,229
-33,371
-32,667
Net cash used in operating activities
-11,735,505
-9,827,193
-11,029,607
-5,905,776
Purchase of property and equipment
21,043
32,486
165,126
372,456
Proceeds from the sale of short-term investments
-
3,000,000
-
-
Proceeds from the sale of investments
10,240,000
-
-
-
Purchase of short-term investments
-
7,768,350
6,480,860
-
Purchase of investments
12,317,643
-
-
-
Net cash used in investing activities
2,669,664
-4,800,836
-6,645,986
-372,456
Payments of deferred offering costs
-
71,093
-29,756
166,755
Proceeds from sale of common stock under public offering, net of offering costs
140,722,254
-
95,514,038
10,774,386
Proceeds from sale of common stock under atm facility, net of offering costs
14,037,289
-
-
-
Proceeds from exercise of stock warrants
441,202
-
124,800
-
Proceeds from exercise of stock options
11,160
33,532
2
6,340
Net cash provided by financing activities
155,282,998
-37,561
95,668,596
10,608,147
Effect of foreign currency on cash
24,665
-12,813
-11,745
-20,552
Net change in cash and cash equivalents
146,241,822
-14,678,403
77,981,258
4,309,363
Cash and cash equivalents beginning of period
79,250,163
93,928,566
15,947,308
17,681,954
Cash and cash equivalents end of period
225,491,985
79,250,163
93,928,566
15,947,308
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common stock under...
$140,722,254
(12643.21%↑ Y/Y)
Proceeds from sale of
common stock under atm...
$14,037,289
Proceeds from exercise of
stock warrants
$441,202
Proceeds from exercise of
stock options
$11,160
(91.62%↑ Y/Y)
Proceeds from the sale of
investments
$10,240,000
something is missing
$4,768,350
Net cash provided by
financing activities
$155,282,998
(13888.00%↑ Y/Y)
Net cash used in
investing activities
$2,669,664
(1466.65%↑ Y/Y)
Effect of foreign
currency on cash
$24,665
(-31.75%↓ Y/Y)
Canceled cashflow
$12,338,686
Net change in cash
and cash...
$146,241,822
(2519.62%↑ Y/Y)
Canceled cashflow
$11,735,505
Stock-based compensation
$978,140
(-30.16%↓ Y/Y)
Depreciation
$90,993
(-5.85%↓ Y/Y)
Amortization of right of use
asset
$39,891
(-5.85%↓ Y/Y)
Prepaid expenses and
other current assets
-$12,044
(-108.25%↓ Y/Y)
Purchase of investments
$12,317,643
Purchase of property and
equipment
$21,043
(-89.23%↓ Y/Y)
Net cash used in
operating activities
-$11,735,505
(-67.77%↓ Y/Y)
Canceled cashflow
$1,121,068
Net loss
-$11,557,002
(-3.51%↓ Y/Y)
Accounts payable and
accrued expenses
-$1,225,630
(-256.55%↓ Y/Y)
Realized gain on
available-for-sale securities
$38,683
Operating lease liability
-$35,983
(-12.56%↓ Y/Y)
Buy us a coffee
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)